Could Curbing Runaway Immune Responses Treat COVID-19?

Drugs targeting patients’ immune systems, rather than the virus itself, could be key to recovery from severe cases of the disease, some researchers suggest.

Written byShawna Williams
| 5 min read
an explosion of red light radiating out from a core

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

ABOVE: © ISTOCK.COM, SAKKMESTERKE

Among the many outstanding questions about COVID-19 is how the same virus, SARS-CoV-2, can kill some patients and leave others unaware they were ever exposed. Clinical evidence combined with hints from laboratory research indicate that for at least some patients with severe cases, the primary danger comes from a runaway immune response that irreparably injures tissue, researchers say. Understanding the mechanisms behind that response could be key to finding a treatment for those patients.

It appears that after infection, the virus replicates itself inside a patient, leading to a disease phase where the immune system mounts an inflammatory response against the invader, says Charles Dela Cruz, a pulmonologist at Yale School of Medicine who is researching COVID-19. Then, in those patients who progress to severe disease, “potentially this inflammatory response is too much and hyper-inflames, causing a lot of side effects in terms of tissue damage ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Shawna was an editor at The Scientist from 2017 through 2022. She holds a bachelor’s degree in biochemistry from Colorado College and a graduate certificate in science communication from the University of California, Santa Cruz. Previously, she worked as a freelance editor and writer, and in the communications offices of several academic research institutions. As news director, Shawna assigned and edited news, opinion, and in-depth feature articles for the website on all aspects of the life sciences. She is based in central Washington State, and is a member of the Northwest Science Writers Association and the National Association of Science Writers.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies